A Study of Ramucirumab (LY3009806) Plus Docetaxel in Participants With Urothelial Cancer

NCT02426125 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

530

Enrollment

INDUSTRY

Sponsor class

Conditions

Urothelial Carcinoma

Interventions

DRUG: Ramucirumab
DRUG: Docetaxel
DRUG: Placebo

Sponsor

Eli Lilly and Company